Altered PTEN expression as a diagnostic marker for the earliest endometrial precancerous changes
Abstract
Introduction: Study was planned to investigate PTEN gene expression in endometrial hyperplasia and carcinoma as analyzed by immunohistochemistry.
Material and Method: This study was conducted on 80 endometrial samples in the Department of Pathology, Gandhi Medical College, Bhopal (January 2012 to August 2016)
Results: 5 out of 5 cases of proliferative endometrium, 3 out of 5 cases of secretory endometrium, 37 [84%] out of 44 cases of simple and complex endometrial hyperplasia without atypia, 8 out of 15 cases of simple and complex endometrial hyperplasia with atypia and 3 out of 11 cases of endometrial carcinoma showed positive PTEN expression.
Conclusion: PTEN is a major gene involved in the pathogenesis of endometrial carcinoma. Our data suggest that decreased PTEN expression was a marker of earliest endometrial pre-cancer lesion and we propose that use of PTEN immunostaining in a clinical setting may be informative in identifying premalignant lesions that are likely to progress to carcinoma.
Downloads
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: https://doi.org/10.3322/caac.20107. Epub 2011 Feb 4
Badar F, Mahmood S. Hospital-based cancer profile at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, pakistan. J Coll Physicians Surg Pak. 2015 Apr;25(4):259-63. doi: https://doi.org/04.2015/JCPSP.259263.
Mutter GL. Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol. 2000 Oct;19(4):301-9.
Boruban MC, Altundag K, Kilic GS, Blankstein J: From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 2008 Apr;17(2):133-8.
Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol. 2002 May;55(5):326-31.
Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006 Oct 10;24(29):4783-91.
Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciriş M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007;203(3):153-62. Epub 2007 Feb 20.
Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007 Mar;46(1):26-32.
Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C: Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001, 61:4311-4.
An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C, et al.: Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin dependent kinase inhibitor,p27. Histopathology 2002, Nov 41(5):437-45.
Bussaglia E, del Rio E, Matias-Guiu X, Prat J: PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Human Pathol 2000, 31:312-7.
Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, KamazawaS, et al.: Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001, 7:892-5.
Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al.:Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000,Jun 7; 92:924-30.
Orbo A, Nilsen MN, Arnes MS, Pettersen I, Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol. 2003 Apr;22(2):141-8.
Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2002 Apr 15;94(8):2185-91.
Geyer JT, López-García MA, Sánchez-Estevez C, Sarrió D, Moreno-Bueno G, Franceschetti I, Palacios J, Oliva E. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol. 2009 Aug;33(8):1157-63. doi: https://doi.org/10.1097/PAS.0b013e3181a902e1.
Visakorpi T: The molecular genetics of prostate cancer. Uorology 2003 Nov, 62:3-9.
Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R: Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002, 33:405-9.
Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, et al.: PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 2004, 130:161-8.
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al.: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997, Sep15,57:3935-40.
Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai 2008 Aug, 91:1161-5.
Lacey JV Jr, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res. 2008 Jul 15;68(14):6014-20. doi: https://doi.org/10.1158/0008-5472.CAN-08-1154.
Mutter GL: EIN Central.endometrium org October 29:1-25.
Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab. 2000 Jun;85(6):2334-8.
Pallares J, Bussaglia E, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, et al.: Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005, 18:719-27.
Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciris, M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007, 203:153-62.
An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C,et al. Alteration of PTEN expression in endometrialcancer is associated with down-regulation of cyclin dependent kinase inhibitor, p27. Histopathology.2002 Nov, 41: 437-45208.
Mutter GL, Lin MC. Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer lnst 2000 Jun 7;92:924-30.
Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F,Haberal A, et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium .Int J Gynecol Cancer. 2006 May, 16 (3): 1412-18.
Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S (2008). Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcionoma. J Med Assoc Thai 2008 Aug 91:1161–1165.
Sarmadi S, Izadi Mood N, Sotoudeh K, Tavangar SM (2009). Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol 2009 Nov, 4:41.
Nehad m.r. abd el-maqsoud et al Differential Expression Patterns of PTEN in Cyclic,Hyperplastic and Malignant Endometrium:Its Relation with ER, PR and Clinicopathological Parameters Journal of the Egyptian Nat. Cancer Inst., Vol. 21, No. 4, December: 323-331, 2009.
Afaf T. Elnashar et a .Immunohistochemical expression of phosphatase and tensin homolog in endometrial hyperplasia and carcinoma Egypt J Patho 2011; 31:2–5.
Samah Mohamed Attia et al. Immunohistochemical study of PTEN and surviving in endometrial proliferative lesions Egyptian Journal of Pathology 2011 Sep, 31:45–53.
Lee H, Choi HJ, Kang CS, Lee HJ, Lee WS, Park CS. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Mod Pathol. 2012 Nov;25(11):1508-15. doi: https://doi.org/10.1038/modpathol.2012.111. Epub 2012 Jul 6.
Summayya Shawana et al Immunoexpression of Cyclin D1 and PTEN in Various Endometrial Pathologies.Journal of the College of Physicians and Surgeons Pakistan 2016, Vol. 26 (4): 277-282.
Orbo A, Nilsen MN, Arnes MS, Pettersen I, Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol. 2003 Apr;22(2):141-8.
Cirpan T, Terek MC, Mgoyi L, Zekioglu O, IscanO, Ozsaran A. Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.Eur J Gynaecol Oncol 2006; 27: 389-92.
Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciris, M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007 Feb, 203:153-62.
Allison KH, Tenpenny E, Reed SD, Swisher EM, Garica RL. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):329-43. doi: https://doi.org/10.1097/PAI.0b013e318159b88e.
Kurman, R.J., Kaminski, P.F. & Norris, H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer, 1985; 56,403-12.
OAI - Open Archives Initiative
